Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In.

Slides:

Advertisements

Similar presentations

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

The genetic basis of myelodysplasia and its clinical relevance

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Myelodysplastic Syndromes

Volume 27, Issue 4, Pages (April 2015)

FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma? by Marine Boulesteix, Mohamed Touati, Julie Abraham, Sandrine Verbeke,

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

by James O. Armitage, and Dan L. Longo

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.

One giant leap for pediatric AMKL

Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.

Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Myelodysplastic Syndromes

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results by Lionel Adès, Miguel A. Sanz,

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

The real world of 'low-risk' MDS: early lessons from the EUMDS registry Theo de Witte, Louise de Swart, Alex Smith, Pierre Fenaux, Raphael Itzykson, Guillermo.

How I treat refractory CLL

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Chronic graft-versus-host disease

Lacramioara Botezatu, Lars C

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care Naitielle de Paula Pantano, RN, Bianca Sakamoto.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients by Marcel W. Bekkenk, Maarten.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study by Radhakrishnan Ramchandren,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

by Jan J. Cornelissen, and Didier Blaise

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Follicular Lymphoma International Prognostic Index

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Cold agglutinin disease

Presentation transcript:

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry by Louise de Swart, Alex Smith, Tom Johnston, Detlef Haase, Jackie Droste, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Eva Hellström-Lindberg, Jaroslav Cermak, Ulrich Germing, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, Antonio Medina Almeida, Krzysztof Madry, Borhane Slama, Agnès Guerci-Bresler, Laurence Sanhes, Odile Beyne-Rauzy, Elisa Luño, David Bowen, and Theo de Witte Blood Volume 122(21):2770-2770 November 15, 2013 ©2013 by American Society of Hematology

Distribution of IPSS & IPSS-R subgroups. Alex Smith et al. Blood 2013;122:2770 ©2013 by American Society of Hematology

Overall Survival. Overall Survival Alex Smith et al. Blood 2013;122:2770 ©2013 by American Society of Hematology